Datwyler, the Swiss-based industrial supplier of state-of-the-art solutions for drug packaging and medical devices, will showcase its current health care offering portfolio at the 2018 CPhI in Philadelphia,including newest solutions in the fields of digital health and wearables. Datwyler recently introducedits new brush electrodes for long-term EEG monitoring which are designed to provide high wearing
comfort for patients while delivering reliable results. The company will also share newest developments
regarding its new facility in Middletown, Delaware, which is scheduled to start production in the second
half of 2018. Trade show attendees can visit Datwyler at booth 2004.
With patient safety as one of Datwyler‘s biggest priorities, the company constantly invests in the most advanced technologies, R&D, design, and production processes to respond to the evolving needs of patients. Asdevelopment partner to the world’s largest pharmaceutical and medical companies, Datwyler has become a key market player in the industry with a strong sense of future trends and the ability to set new industry standards. “Digital health is currently one of the hottest trends in the health care industry and we believe that it has the potential to increase patient safety and advance global health care at the same time”, says Norbert Haberland, Vice President New Processes & Products at Datwyler Sealing Solutions. “We have been researching digital health since 2014 and are among the frontrunners in this field. So far, we have been exploring the possibilities of wearable devices and have set up research partnerships to develop solutions for embedded electronics and sensing elements.”
Brush electrodes: Responding to the evolving needs of patients
Datwyler’s new brush electrodes are among the most recent results of the company’s R&D efforts. They are
Datwyler’s proposition for long-term EEG monitoring with focus on patient comfort. The electrodes are based on a flexible conductive polymer and customizable design to ensure comfort during monitoring. The electrodes allow dry signal acquisition which eliminates the use of gels and decreases skin irritation significantly. The specific design and characteristics allow usage without special skin preparation and freedom of area for monitoring. A hospital environment is not necessarily needed.
Strengthening Datwyler’s position in the U.S. pharmaceutical market
Datwyler is strongly committed to providing U.S. customers with locally produced components and optimized supply chains. Therefore, the company is investing more than $100 million into a new facility in Middletown,Delaware, which is planned, designed and built in accordance with Datwyler’s First Line standard. With production scheduled to start in September 2018, the new facility will manufacture high-quality elastomer components for injectable drug delivery systems. Once it is fully up and running, the highly automated plant will provide jobs for around 120 employees.
Commitment to the highest level of quality
The importance of cleanroom manufacturing will significantly increase in the next few years. Patient safety as one of the crucial factors for the pharmaceutical industry, relies, to a great extent, on high-tech drug
administration solutions and technologies which are increasingly produced in a cleanroom environment.
Datwyler’s production standard First Line, which will be applied in the Delaware facility, is specially designed to manufacture pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP)environment conforming to the highest industry standards. This innovative approach to manufacturing exceeds the most stringent quality standards of the European and US regulatory authorities and is certified to ISO 15378.
DATWYLER | HEALTH CARE
The Datwyler Group is an international supplier of state-of-the-art industrial components with leading positions in global and regional market segments. As technological leader, the Datwyler Group delivers added value to its customers in all markets served. In its Sealing Solutions division, Datwyler provides customised sealing solutions to manufacturers and companies which operate in the health care and automotive industry, as well as the market segments civil engineering and consumer goods. Within the health care unit, Datwyler develops,designs and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment of tomorrow. The company develops complex and unique coatings and rubber compounds enabling customers to fill syringes with medicine and thus gives numerous people acrosthe globe access to new medications. The products and services of Datwyler are built on high-quality material,innovative technologies, outstanding engineering and process know-how. With a global manufacturing footprint on three continents, sales in over 100 countries and more than 7,000 employees, the Datwyler Group generates an annual revenue of approx. € 1’200 million. Looking back onto more than 100 years of history, Datwyler is a reliable partner, now and in the future.
Datwyler Sealing Solutions: Simone Ramser, Vice President Communications,
firstname.lastname@example.org, +41 41 875 1410
Burson-Marsteller GmbH, Amelie Mayer-Quien, email@example.com, +49 69 238 0967
Photos (in print quality): http://www.datwyler.com/en/media/image-library/